Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07821411) titled 'A Real-World Study of Ofatumumab in Multiple Sclerosis Patients in Germany and Japan' on Sept. 9.

Study Type: Observational

Primary Sponsor: Novartis Pharmaceuticals

Condition: Multiple Sclerosis

Recruitment Status: Not recruiting

Date of First Enrollment: July 31, 2026

Target Sample Size: 5000

Countries of Recruitment: Switzerland

To know more, visit https://clinicaltrials.gov/study/NCT07821411

Published by HT Digital Content Services with permission from Health Daily Digest....